Safety and Efficacy Trial of Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease
Latest Information Update: 04 Apr 2025
At a glance
- Drugs Plerixafor (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions; Therapeutic Use
- 30 Mar 2025 Status changed from active, no longer recruiting to completed.
- 03 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 08 Aug 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2025.